Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

Completed · Phase 2 · Has a placebo group

Conditions studied: Neovascular Age-elated Macular Degeneration (Wet AMD), Exudative Macular Degeneration

In brief

This study will assess the safety and efficacy of LFG316 in patients with age related macular degeneration.

Key facts

Study ID
NCT01535950
Run by
Novartis Pharmaceuticals
People needed
43
Starts
2012-02-01
Expected to finish
2013-07-01
Last updated by the study team
2020-12-19

Who can join

Age: 55 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.